Effects of Psilocybin in Anorexia Nervosa

This open-label pilot study seeks to investigate the safety and efficacy of psilocybin in persons with chronic anorexia nervosa (AN). Psilocybin has previously been demonstrated to decrease depression and anxiety and increase long-term positive behaviour change in other populations.

The investigators seek to determine whether similar changes can be safely produced in people with AN when psilocybin is administered in a supportive setting with close follow-up. The investigators’ primary hypotheses are that psilocybin is safe to administer in people with AN, that it will reduce measures of anxiety and depression, and that it will lead to increased quality of life.

The investigators will also assess a number of exploratory measures related to eating disorder pathophysiology.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account
Status Recruiting
Start date 26 August 2019
End date 01 December 2022
Chance of happening 100%
Phase Phase I
Design Open
Type Interventional
Generation First
Participants 18
Sex All
Age 18- 65
Therapy Yes

Trial Details

This open-label pilot study seeks to investigate the safety and efficacy of psilocybin in persons with chronic anorexia nervosa (AN). Psilocybin has previously been demonstrated to decrease depression and anxiety and increase long-term positive behavior change in other populations. The investigators seek to determine whether similar changes can be safely produced in people with AN when psilocybin is administered in a supportive setting with close follow-up. The investigators' primary hypotheses are that psilocybin is safe to administer in people with AN, that it will reduce measures of anxiety and depression, and that it will lead to increased quality of life. The investigators will also assess a number of exploratory measures related to eating disorder pathophysiology.

NCT Number NCT04052568

Sponsors & Collaborators

Johns Hopkins University
Johns Hopkins University (Medicine) is host to the Center for Psychedelic and Consciousness Research, which is one of the leading research institutes into psychedelics. The center is led by Roland Griffiths and Matthew Johnson.

Measures Used

Eating Disorder Examination Questionnaire
The Eating Disorder Examination Questionnaire (EDE-Q) is a self-report questionnaire that has been adapted from the Eating Disorder Examination (EDE).

Eating Disorder Examination Interview
The Eating Disorder Examination Interview (EDE) is a semi-structured interview conducted by a clinician that has been modified to reflect the current DSM-5 diagnosis. The EDE is rated using four subscales; restraint, eating concern, shape concern and weight concern.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.
0 Comments
Inline Feedbacks
View all comments